$PLX
Protalix BioTherapeutics, Inc. Stock $plx

$plx Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000114420415047801 Filed on August 10, 2015

Income Statement

Concept	2015 Q3	2015 Q2	2014 Q2
Revenue	$1.336M	$1.336M	$2.425M
YoY Change	-44.24%	-44.91%	7.11%
Cost Of Revenue	$223.0K	$225.0K	$1.605M
YoY Change	-87.6%	-85.98%	21.78%
Gross Profit	$1.113M	$1.111M	$1.081M
YoY Change	-41.7%	2.78%	-38.09%
Gross Profit Margin	83.31%	83.16%	44.58%
Selling, General & Admin	$2.163M	$2.001M	$1.566M
YoY Change	7.5%	27.78%	-28.23%
% of Gross Profit	194.34%	180.11%	144.87%
Research & Development	$5.068M	$6.023M	$7.076M
YoY Change	-37.06%	-14.88%	-11.44%
% of Gross Profit	455.35%	542.12%	654.58%
Depreciation & Amortization	$590.0K	$600.0K	$800.0K
YoY Change	-25.32%	-25.0%	-10.11%
% of Gross Profit	53.01%	54.01%	74.01%
Operating Expenses	$7.231M	$8.024M	$8.642M
YoY Change	-28.15%	-7.15%	-15.04%
Operating Profit	-$5.002M	-$5.584M	-$5.447M
YoY Change	-19.43%	2.52%	-20.99%
Interest Expense	-$1.010M	-$600.0K	-$670.0K
YoY Change	-43.89%	-10.45%	-1216.67%
% of Operating Profit
Other Income/Expense, Net	-$1.013M	-$599.0K	-$672.0K
YoY Change	-43.78%	-10.86%	-1278.95%
Pretax Income	-$6.020M	-$6.180M	-$6.120M
YoY Change	-24.84%	0.98%	-10.53%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$3.820M	-$5.071M	-$6.119M
YoY Change	-52.31%	-17.13%	-10.5%
Net Earnings / Revenue	-285.93%	-379.57%	-252.33%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.40	-$0.54	-$0.66
COMMON SHARES
Basic Shares Outstanding	94.15M shares	93.60M shares	93.61M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q3	2015 Q2	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$34.20M	$43.20M	$71.10M
YoY Change	-43.28%	-39.24%	114.8%
Cash & Equivalents	$34.25M	$43.24M	$71.14M
Short-Term Investments
Other Short-Term Assets	$2.716M	$2.300M	$2.000M
YoY Change	29.33%	15.0%	-44.44%
Inventory	$6.339M	$6.368M	$7.135M
Prepaid Expenses
Receivables	$4.573M	$1.900M	$2.097M
Other Receivables	$0.00	$0.00	$1.988M
Total Short-Term Assets	$47.88M	$53.90M	$82.36M
YoY Change	-32.77%	-34.56%	79.32%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.957M	$10.40M	$12.44M
YoY Change	-15.95%	-16.39%	-17.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.700M	$1.700M	$1.800M
YoY Change	0.0%	-5.56%	28.57%
Total Long-Term Assets	$11.62M	$12.10M	$14.29M
YoY Change	-14.51%	-15.31%	-12.75%
TOTAL ASSETS
Total Short-Term Assets	$47.88M	$53.90M	$82.36M
Total Long-Term Assets	$11.62M	$12.10M	$14.29M
Total Assets	$59.49M	$66.00M	$96.65M
YoY Change	-29.84%	-31.71%	55.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.100M	$4.300M	$3.600M
YoY Change	13.89%	19.44%	-7.69%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$22.85M	$25.50M	$27.18M
YoY Change	-6.28%	-6.18%	2.07%
LONG-TERM LIABILITIES
Long-Term Debt	$67.80M	$67.70M
YoY Change
Other Long-Term Liabilities	$37.40M	$37.90M	$42.00M
YoY Change	-8.11%	-9.76%	-11.95%
Total Long-Term Liabilities	$105.2M	$105.6M	$109.3M
YoY Change	-2.73%	-3.35%	129.23%
TOTAL LIABILITIES
Total Short-Term Liabilities	$22.85M	$25.50M	$27.18M
Total Long-Term Liabilities	$105.2M	$105.6M	$109.3M
Total Liabilities	$128.0M	$131.1M	$136.4M
YoY Change	-3.39%	-3.91%	83.66%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$68.51M	-$65.14M	-$39.79M
YoY Change
Total Liabilities & Shareholders Equity	$59.49M	$66.00M	$96.65M
YoY Change	-29.84%	-31.71%	55.12%

Cashflow Statement

Concept	2015 Q3	2015 Q2	2014 Q2
OPERATING ACTIVITIES
Net Income	-$3.820M	-$5.071M	-$6.119M
YoY Change	-52.31%	-17.13%	-10.5%
Depreciation, Depletion And Amortization	$590.0K	$600.0K	$800.0K
YoY Change	-25.32%	-25.0%	-10.11%
Cash From Operating Activities	-$8.660M	-$5.350M	-$6.520M
YoY Change	-9.32%	-17.94%	-19.61%
INVESTING ACTIVITIES
Capital Expenditures	$130.0K	$230.0K	$110.0K
YoY Change	-48.0%	109.09%	-84.29%
Acquisitions
YoY Change
Other Investing Activities	-$40.00K	-$20.00K	-$80.00K
YoY Change	33.33%	-75.0%	300.0%
Cash From Investing Activities	-$170.0K	-$250.0K	-$200.0K
YoY Change	-34.62%	25.0%	-72.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	530.0K	0.000
YoY Change	-100.0%		-100.0%
NET CHANGE
Cash From Operating Activities	-8.660M	-5.350M	-6.520M
Cash From Investing Activities	-170.0K	-250.0K	-200.0K
Cash From Financing Activities	0.000	530.0K	0.000
Net Change In Cash	-8.830M	-5.070M	-6.720M
YoY Change	-9.9%	-24.55%	-23.64%
FREE CASH FLOW
Cash From Operating Activities	-$8.660M	-$5.350M	-$6.520M
Capital Expenditures	$130.0K	$230.0K	$110.0K
Free Cash Flow	-$8.790M	-$5.580M	-$6.630M
YoY Change	-10.31%	-15.84%	-24.74%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	101000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-565000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	31000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	31000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	139000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	65520000	USD
CY2014Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1555000	USD
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	94151318	shares
CY2014Q4	us-gaap	Inventory Net InventoryNet	6667000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11282000	USD
CY2014Q4	us-gaap	Deferred Costs DeferredCosts	113000	USD
CY2014Q4	us-gaap	Assets Assets	78470000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	93000	USD
CY2014Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3951000	USD
CY2014Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	15496000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	6763000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	26210000	USD
CY2015Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	67670000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43238000	USD
CY2014Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	67464000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	37232000	USD
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	912000	USD
CY2014Q4	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	2253000	USD
CY2014Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	107861000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	134071000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54767000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-55601000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	78470000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1884000	USD
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2202000	USD
CY2015Q2	us-gaap	Inventory Net InventoryNet	6368000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-13464000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	577000	USD
	us-gaap	Depreciation Depreciation	1628000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	133000	USD
	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	102000	USD
	plx	Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement	25000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	220000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-4369000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	397000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-822000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	180000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-14859000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	371000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-15254000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71144000	USD
	plx	Increase In Liabilities For Property Plant And Equipment IncreaseInLiabilitiesForPropertyPlantAndEquipment	170000	USD
	plx	Cashless Exercise Of Stock Options CashlessExerciseOfStockOptions		USD
	plx	Cashless Exercise Of Stock Options CashlessExerciseOfStockOptions	12000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1553000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1527000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash		USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	15000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-26946000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	190000	USD
	plx	Share Based Compensation Restricted Stock Awards Net Of Forfeitures ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures	387000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	43000	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	-39790000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	595000	USD
	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	2501	shares
	plx	Share Based Compensation Restricted Stock Awards Net Of Forfeitures ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures	378000	USD
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	534000	USD
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
	us-gaap	Revenues Revenues	8174000	USD
	us-gaap	Revenues Revenues	9121000	USD
	plx	Other Gains Losses OtherGainsLosses	1539000	USD
	plx	Other Gains Losses OtherGainsLosses	948000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	4439000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	5678000	USD
	us-gaap	Gross Profit GrossProfit	5274000	USD
	us-gaap	Gross Profit GrossProfit	4391000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13233000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15228000	USD
	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	2649000	USD
	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	4199000	USD
	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	10584000	USD
	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	11029000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4005000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5277000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9315000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11915000	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	1799000	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	1789000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	71000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	240000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1728000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1549000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	93418666	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	92754640	shares
CY2014Q2	us-gaap	Gross Profit GrossProfit	1081000	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6471000	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7076000	USD
CY2015Q2	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	1514000	USD
CY2014Q2	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	2114000	USD
CY2015Q2	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	4957000	USD
CY2014Q2	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	4962000	USD
CY2015Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2092000	USD
CY2014Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1566000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4472000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5447000	USD
CY2015Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	642000	USD
CY2014Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	874000	USD
CY2015Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	43000	USD
CY2014Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	202000	USD
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-599000	USD
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-672000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-5071000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-6119000	USD
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	93635213	shares
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	92820897	shares
CY2015Q2	us-gaap	Revenues Revenues	3782000	USD
CY2014Q2	us-gaap	Revenues Revenues	2425000	USD
CY2015Q2	plx	Other Gains Losses OtherGainsLosses	834000	USD
CY2014Q2	plx	Other Gains Losses OtherGainsLosses	261000	USD
CY2015Q2	us-gaap	Cost Of Revenue CostOfRevenue	2039000	USD
CY2014Q2	us-gaap	Cost Of Revenue CostOfRevenue	1605000	USD
CY2015Q2	us-gaap	Gross Profit GrossProfit	2577000	USD
	plx	Number Of Subsidiaries NumberOfSubsidiaries	2	item
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18844777	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19780594	shares
CY2014Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18778154	shares
CY2015Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20167947	shares
CY2015Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1239000	USD
CY2014Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1616000	USD
CY2015Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	117000	USD
CY2014Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	132000	USD
CY2015Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5012000	USD
CY2014Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4919000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	770000	USD
CY2015Q2	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	53800000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	dei	Trading Symbol TradingSymbol	PLX
	dei	Entity Registrant Name EntityRegistrantName	PROTALIX BIOTHERAPEUTICS, INC.
	dei	Document Type DocumentType	10-Q
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Entity Central Index Key EntityCentralIndexKey	0001006281

Files In Submission

Name	View Source	Status
0001144204-15-047801-index-headers.html	Edgar Link	pending
0001144204-15-047801-index.html	Edgar Link	pending
0001144204-15-047801.txt	Edgar Link	pending
0001144204-15-047801-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
plx-20150630.xml	Edgar Link	completed
plx-20150630.xsd	Edgar Link	pending
plx-20150630_cal.xml	Edgar Link	unprocessable
plx-20150630_def.xml	Edgar Link	unprocessable
plx-20150630_lab.xml	Edgar Link	unprocessable
plx-20150630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v416648_10q.htm	Edgar Link	pending
v416648_ex31-1.htm	Edgar Link	pending
v416648_ex31-2.htm	Edgar Link	pending
v416648_ex32-1.htm	Edgar Link	pending
v416648_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PLX
Protalix BioTherapeutics, Inc. Stock $plx

2015 Q3 Form 10-Q Financial Statement

#000114420415047801 Filed on August 10, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLX Protalix BioTherapeutics, Inc. Stock $plx

2015 Q3 Form 10-Q Financial Statement

#000114420415047801 Filed on August 10, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLX
Protalix BioTherapeutics, Inc. Stock $plx